Concourse Financial Group Securities, Inc. Prelude Therapeutics Inc Transaction History
Concourse Financial Group Securities, Inc.
- $1.52 Billion
- Q1 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding PRLD
# of Institutions
59Shares Held
34.2MCall Options Held
200Put Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$39.3 Million1.16% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$36.4 Million0.61% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.13MShares$14.9 Million0.4% of portfolio
-
Boxer Capital, LLC San Diego, CA2.57MShares$9.25 Million0.63% of portfolio
-
Black Rock Inc. New York, NY1.1MShares$3.95 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $131M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...